anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A medical information processing apparatus of an embodiment includes processing circuitry. The processing circuitry acquires biometric data regarding a subject. The processing circuitry identifies reference data regarding a first feature amount on the basis of the biometric data. The processing circuitry acquires a second feature amount by inputting the first feature amount included in the biometric data into a model capable of mutually converting the first feature amount and the second feature amount. The processing circuitry derives pseudo-feature data regarding the first feature amount simulated by inputting the second feature amount into the model. The processing circuitry determines reliability scores with respect to the biometric data on the basis of the reference data and the pseudo-feature data.
Patients with periodontitis which is defined by interdental clinical attachment loss (CAL) ≥ 2 non-adjacent teeth, or Buccal or Oral CAL ≥ 3 mm with probing pocket depth (PPD) \> 3 mm is detectable at ≥2 teeth. All patients should be indicated for periodontal surgery.
OBJECTIVES: Gender difference in the outcome after type A aortic dissection (TAAD) surgery remains an issue of ongoing debate. In this study, we aimed to evaluate the impact of gender on the short- and long-term outcome after surgery for TAAD.
METHODS: A multicentre European registry retrospectively included all consecutive TAAD surgery patients between 2005 and 2021 from 18 hospitals across 8 European countries. Early and late mortality, and cumulative incidence of aortic reoperation were compared between genders.
RESULTS: A total of 3902 patients underwent TAAD surgery, with 1185 (30.4%) being females. After propensity score matching, 766 pairs of males and females were compared. No statistical differences were detected in the early postoperative outcome between genders. Ten-year survival was comparable between genders (47.8% vs 47.1%; log-rank test, P = 0.679), as well as cumulative incidences of distal or proximal aortic reoperations. Ten-year relative survival compared to country-, year-, age- and sex-matched general population was higher among males (0.65) compared to females (0.58). The time-period subanalysis revealed advancements in surgical techniques in both genders over the years. However, an increase in stroke was observed over time for both populations, particularly among females.
CONCLUSIONS: The past 16 years have witnessed marked advancements in surgical techniques for TAAD in both males and females, achieving comparable early and late mortality rates. Despite these findings, late relative survival was still in favour of males.
BACKGROUND: Mitotic clonal expansion (MCE) is a prerequisite for preadipocyte differentiation and adipogenesis. Epigallocatechin gallate (EGCG) has been shown to inhibit preadipocyte differentiation. However, the exact molecular mechanisms are still elusive.
PURPOSE: This study investigated whether EGCG could inhibit adipogenesis and lipid accumulation by regulating the cell cycle in the MCE phase of adipogenesis and its underlying molecular mechanisms.
METHOD: 3T3-L1 preadipocytes were induced to differentiate by a differentiation cocktail (DMI) and were treated with EGCG (25-100 μM) for 9, 18, and 24 h to examine the effect on MCE, or eight days to examine the effect on terminal differentiation. C57BL/6 mice were fed a high-fat diet (HFD) for three months to induce obesity and were given EGCG (50 or 100 mg/kg) daily by gavage.
RESULTS: We showed that EGCG significantly inhibited terminal adipogenesis and lipid accumulation in 3T3-L1 cells and decreased expressions of PPARγ, C/EBPα, and FASN. Notably, at the MCE phase, EGCG regulated the cell cycle in sequential order, induced G0/G1 arrest at 18 h, and inhibited the G2/M phase at 24 h upon DMI treatment. Meanwhile, EGCG regulated the expressions of cell cycle regulators (cyclin D1, cyclin E1, CDK4, CDK6, cyclin B1, cyclin B2, p16, and p27), and decreased C/EBPβ, PPARγ, and C/EBPα expressions at MCE. Mechanistic studies using STAT3 agonist Colivelin and antagonist C188-9 revealed that EGCG-induced cell cycle arrest in the MCE phase and terminal adipocyte differentiation was mediated by the inhibition of JAK2/STAT3 signaling cascades and STAT3 (Tyr705) nuclear translocation. Furthermore, EGCG significantly protected mice from HFD-induced obesity, reduced body weight and lipid accumulations in adipose tissues, reduced hyperlipidemia and leptin levels, and improved glucose intolerance and insulin sensitivity. Moreover, RNA sequencing (RNA-seq) analysis showed that the cell cycle changes in epididymal white adipose tissue (eWAT) were significantly enriched upon EGCG treatment. We further verified that EGCG treatment significantly reduced expressions of adipogenic factors, cell cycle regulators, and p-STAT3 in eWAT.
CONCLUSION: EGCG inhibits MCE, resulting in the inhibition of early and terminal adipocyte differentiation and lipid accumulation, which were mediated by inhibiting p-STAT3 nucleus translocation and activation.
PURPOSE: Kyungokhwan(Korean medicinal pill) containing ginseng, Poria cocos, honey, and Rehmannia glutinosa var. purpurea, and additionally containing Poria cocos, Atractylodes macrocephala Koidzumi, and Licorice powder is provided to ensure convenience, to minimize efficacy reduction, and to reduce side effects. CONSTITUTION: Kyungokhwan contains 10 parts by weight of ginseng, 10-30 parts by weight of Poria cocos, 50-70 parts by weight of honey, and 60-80 parts by weight of Rehmannia glutinosa var. purpurea, and additionally contains 3-7 parts by weight of Poria cocos, 3-7 parts by weight of Atractylodes macrocephala Koidzumi, and 3-7 parts by weight of Licorice powder. A method for manufacturing Kyungokhwan comprises: a step of mixing Poria cocos powder, honey, and pulverized Rehmannia glutinosa var. purpurea; a step of heating the mixture in a water bath for 72 hours or more and cooling at room temperature for 24 hours or more; and a step of heating the mixture in the water bath for 24 hours or more.
This condition will control for any effects of symptom measurement reactivity in patients receiving routine fibromyalgia medical care. After the 3-month assessment, the yoga intervention program will be provided to these patients.
PURPOSE:To obtain an antipyretic agent which can be preserved stably, by coating granular antiacid and/or granular aspirin with a coating agent soluble in water and an acidic aqueous solution, thereby preventing the degradation of the antiacid and aspirin caused by compounding. CONSTITUTION:A stable antipyretic agent can be prepared by coating granular antiacid (e.g. magnesium carbonate, synthetic hydrotalcite, etc.) and/or granular acetylsalicylic acid (aspirin). To assure the exhibition of the antiacid effect in gastric juice, the coating agent is preferably the one soluble in water or an acidic aqueous solution (e.g. sugar, PEG-6000, etc.). Although aspirin and an antiacid react with each other by compounding and their mixture is unstable, the composition can be stabilized by coating at least one of the granular components, preferably both components.
The purpose of this study is to determine whether the drug, bethanechol, could potentially be used in combination with chemotherapy regimen gemcitabine and nab-paclitaxel and surgery to decrease the chance of the cancer coming back after it is removed. Animal models have shown that treatment with bethanechol can inhibit cancer growth and spread. The chemotherapy regimen nab-paclitaxel for use in combination with gemcitabine to treat patients with metastatic pancreatic cancer is FDA approved. Although bethanechol is FDA approved, in this study its use is experimental. The aim of the study is to show that the medication is easy to tolerate and that it shows signs of slowing cancer cell growth. The investigators hypothesize that treatment with bethanechol will alter nerve conduction within tumors by stimulating the parasympathetic nervous system and reduce tumor proliferation, decrease CD44+ expression in cancer cells, decrease tumor growth rate resulting in an improved R0 resection rate.
The invention relates to a navel applying plaster for treating chronic diarrhea and a preparation method and application thereof, wherein the navel applying plaster comprises the following raw materials in parts by weight: 1 to 10 parts of clove, 1 to 10 parts of evodia rutaecarpa, 3 to 12 parts of rice vinegar and 3 to 12 parts of water. The navel application plaster for treating chronic diarrhea is characterized in that the fructus evodiae is immature fruits of rutaecarpa which is a rutaecarpa material deciduous shrub or a small arbor plant. Evodia rutaecarpa, fructus evodiae is pungent, bitter and hot in property, enters liver, spleen and stomach channels, and has the effects of soothing liver, descending qi, lowering adverse qi, relieving vomiting, warming middle energizer, relieving pain, dispelling cold and eliminating dampness. Flos Caryophylli is a plant of Myrtaceae, and is prepared from flower bud and fruit. The nature and the temperature; 2, pungent taste; it enters stomach, spleen and kidney meridians. Has effects in warming middle warmer, lowering adverse qi, invigorating kidney, and tonifying yang. The clove and the evodia rutaecarpa are used for treating clinically most common diarrhea caused by deficiency-cold of spleen and stomach and water-damp retention, and have the effects of warming spleen and stomach for dispelling cold, eliminating dampness and inducing diuresis, and finally achieving the aim of relieving diarrhea.
PEG-rIL-29 (also known as PEG-interferon lambda) is a unique Type III interferon molecule that has demonstrated antiviral activity when administered weekly for 4 weeks to treatment-relapsed and treatment-naive subjects with genotype 1 hepatitis C virus (HCV) infection. Because PEG-rIL-29 binds to a unique receptor with a more limited distribution than the receptor for interferon (IFN)-α, it may have the potential to treat HCV without some of the treatment-limiting side effects associated with IFN-α-based therapies. The purpose of this Phase 2a/b randomized, controlled, multicenter study is to compare the safety and efficacy of PEG-rIL-29 and peginterferon alfa-2a, both administered subcutaneously weekly for up to 48 weeks in combination with daily oral ribavirin, in treatment-naive subjects with chronic genotype 1, 2, 3, or 4 HCV infection. The initial part of the study (Phase 2a) will be conducted as an open-label study; the second part of the study (Phase 2b) will be conducted as a blinded study. The above information provided in this listing is specific to the Phase 2b portion of the study. In addition, two small open-label substudies will be conducted to evaluate the efficacy of 24-week treatment with PEG-rIL-29 and ribavirin in subjects with HCV genotype 1 who have a particular genetic polymorphism associated with favorable response (n=60) and to evaluate the efficacy of 16-week treatment with PEG-rIL-29 and ribavirin in subjects with HCV genotype 2 or 3 (n=30).
Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75, 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL. Subjects will then go on to receive institutional standard of care.
Major Depressive Disorder patients will receive the exercise intervention for 12 weeks as an add-on to their usual treatment (antidepressant treatment prescribed by the attending specialist). They will gradually increase their levels of physical activity by daily walking and will conduct aerobic and muscle strength activities 2 days per week. The program will be supervised by a physical education and sports professional.
This is a phase 4 single-center, open-label, single-arm study evaluating the ability of 99mTc-TM to identify clipped nodes in primary breast cancer patients receiving NAC and subsequent Sentinel Lymph Node Biopsy (SLNB) as practice compared to published historical data . Sixty-four (64) patients (≥18 years) diagnosed with breast cancer and who are evaluated as having a favorable response (i.e., at least partial clinical response in the breast) to chemotherapy during the mid-treatment evaluation will be evaluated in this study. Patients will have suspicious lymph nodes assessed and one biopsied for pathological evaluation and clipped during the course of the patients' medical work-up. Patients will undergo NAC treatment and have a mid-treatment evaluation to assess response to the chemotherapy. Patients with a favorable response will complete NAC followed by identification of the clipped node and sentinel lymph nodes and standard lymph node assessment. Patients with an unfavorable response (i.e., no response to the NAC) will continue NAC but will not continue to participate in the study. All study patients undergoing SLNB will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) preoperatively. If no signal is detected within 30-60 minutes, patients may also be injected with BD (up to 10 cc), intraoperatively. Pain at injection site will be assessed pre-injection and at 1 minute after the 99mTc-TM injection.

It is anticipated that the majority of patients enrolled will receive NAC treatment. Although chemotherapy will be the primary neoadjuvant treatment used in this study, if the investigator feels the patient will benefit more from hormonal therapy, a hormonal treatment will be administered.
The project is mainly based on classic field trial study design to compare impacts of different fasting patterns on host metabolic health. Under the condition of controlled diet background, individual N-of-1 study design is also organically integrated to compare personalized responses for standard meal tests. Participants will be required to wear continuous glucose monitoring (CGM) for 14 days. The diet intervention will be carried out after wearing CGM on Day 1. Then, all participants will be divided into three groups: energy-restricted diet (ERD), 18:6 time-restricted diet (TRD), and normal diet (ND). During Day 3 to Day 12, ERD restricts daily total energy intake within 1200-1500 kcal without meal timing limits, while TRD restricts the daily feeding window from 10:00 to 16:00, without total energy intake restriction. ND will maintain volunteers' original eating habits and rhythms as the control group. Individual N-of-1 trial design will be employed to all participants during Day 3 to Day 12 to compare the difference of postprandial glucose response to white bread or plain oats. These two standard breakfasts will appear in pseudo-random order. The TRD group needs to adjust the breakfast time to after 10:00 in the intervention periods.
Methods, systems, and computer-readable media are provided for aggregating, partitioning, and storing healthcare data. Healthcare data is collected from various disparate healthcare data sources. The data is aggregated into batches of the same type of data. From here, the data is partitioned according to the data's originating healthcare data source. The aggregated and partitioned healthcare data is then stored in a long term storage data store. This system of storing healthcare data allows for efficient retrieval and processing by computing solutions that need access to batches of healthcare data. The system also reduces costs associated with storing data as duplicate storage is eliminated.
The coronavirus disease 2019 (COVID-19) pandemic has brought severe consequences worldwide. Indonesia is one of the countries which has been affected by this pandemic. The examination, treatment, and monitoring of individuals with COVID-19 often requires them to be in a hospital isolation ward. There are a lot of factors which could negatively affect the mental health of such patients during their isolation, to the point that they develop significantly debilitating conditions.

Several psychotherapy interventions have been known to be effective during a pandemic situation. The interventions include those based on techniques of relaxation, managing thoughts and feelings, and mindfulness. These methods could help reducing negative and catastrophic thoughts about the future, reducing distress level and hyperarousal, and other beneficial effect. However, due to the high transmission rate of SARS-CoV-2 virus (severe acute respiratory syndrome-coronavirus 2), face-to-face therapy sessions are rendered difficult to hold under the circumstances. Thus, we conducted a pilot study to test the impact of a video-based psychotherapy intervention on distress and well-being in hospitalized COVID-19 patients in a medical isolation ward.

This pilot study included 42 patients with COVID-19, aged 20-59. Participants watched three brief psychotherapy videos covering relaxation, managing thoughts and emotions, and mindfulness. Before and after watching the videos, patients were asked to complete the Subjective Units of Distress Scale (SUDS). 31 subjects experienced a significant median decrease in SUDS score after the intervention. The effect size was 0.485, with a 95% confidence interval of 0.302 to 0.634. Our brief video-based psychotherapy intervention may have a positive effect on reducing distress in hospitalized COVID-19 patients in areas with scarce resources. This study could be used as a reference for future studies regarding the method of choice for delivering psychotherapy intervention for patients in isolation ward during the COVID-19 pandemic.
Herpes zoster (HZ), also known shingles, is a viral disease caused by the varicella-zoster virus. It is considered a local reactivation of varicella (chicken pox). The rash of herpes zoster is characterized by vesicles that appear following a single dermatome (the territory that is innervated by one spinal nerve). These vesicles may be very painful and cause discomfort due to draining and crusting. When a person becomes sick with shingles healthcare professionals prescribe systemic (oral) treatment with antivirals (e.g. acyclovir) and pain medication according to the type and severity. To treat the local lesions caused by shingles, over the centuries, patients have been treated with drying solutions and drying powders. This practice has been passed on through the years without any evidence supporting its effectiveness, in all likelihood due to the fact that the rash is self-limited to 2 to 3 weeks. Recently, new evidence has shown that the vesicles that appear with the shingles rash are not superficial but involve deeper areas of the skin and should be considered partial thickness wounds. Since 1962, it has become clear that partial thickness wounds benefit from occlusive therapy (keeping wounds closed and avoiding drying) such as dressings and occlusive gels that keep the wound wet rather than allowing it to dry.

In this clinical trial the investigators believe that given this information, using occlusive therapy with a hydrocolloid dressing or a silicone-based gel may heal the rash of herpes zoster, decrease pain and improve the quality of life, much faster than the treatment currently used of drying the area with powders and solutions.
BACKGROUND: Colorectal cancer stands as one of the most prevalent malignant tumors affecting the digestive tract, posing a significant threat to human health. Its incidence and fatality rates rank third and second, respectively, among malignant tumors. This study seeks to analyze the efficacy of combining fluorouracil intraperitoneal perfusion chemotherapy with intravenous chemotherapy in patients following radical resection of colorectal cancer.
METHODS: This retrospective study analyzed the medical records of 65 patients who underwent radical resection of colorectal cancer at the Affiliated Hospital of Shandong University of Traditional Chinese Medicine from January 2011 to January 2013. These patients were divided into two groups based on their treatment methods: the control group (CG, n = 31, receiving intravenous chemotherapy) and the observation group (OG, n = 32, receiving fluorouracil intraperitoneal perfusion chemotherapy + intravenous chemotherapy). After 6 cycles of treatment, the study compared clinical symptoms, Karnofsky score, body weight, adverse reactions, local recurrence, and liver metastasis between the two groups.
RESULTS: The OG demonstrated superior efficacy in controlling recurrence and metastasis compared to the CG (p < 0.05). However, there were no significant differences observed in clinical symptoms, quality of life, body weight, and drug safety between the two groups (p > 0.05).
CONCLUSION: Intraperitoneal infusion chemotherapy with fluorouracil significantly impacts the control of recurrence and metastasis following radical resection of colorectal cancer. It also offers valuable references for developing clinical treatment protocols for these patients.
Genotype (GT)1 HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
FIELD: medicine, narcology, phytotherapy, pharmacy. SUBSTANCE: invention relates to development of medicinal species used for prophylaxis and treatment of patients with pathological attraction to alcohol. Species consists of the following medicinal plants: common wormwood herb, common milfoil herb, thyme herb, dioecious nettle leaves, tansy inflorescences, swampy sweet flag roots taken in the following ratio of components: common wormwood herb, 2; common milfoil herb, 2; thyme herb, 1; dioecious nettle leaves, 1; tansy inflorescences, 1; swampy sweet flag, 3. Treatment with the proposed species results to positive effect by arresting the pathological attraction to alcohol and depressive dystrophic symptomatology in 60 patients suffering with chronic alcoholism. EFFECT: enhanced effectiveness of species. 2 tbl
The food supplement is intended to complement to the normal diet and comprises a concentrated source of substances with a nutritional and / or physiological effect. The purpose of the utility model is to create a combined composition contributing to the maintenance of the normal physiological function of the kidneys and the excretory system. The supplement has the ability to dissolve kidney stones and sand formed by uric acid and to prevent it from forming. It has diuretic, anti-inflammatory, antimicrobial and spasmolytic action. The food supplement includes the active ingredients in the following amounts: polyoxyethylene sorbitan monooleate - 50 mg, vitamin A - 0.45 mg (450 ?g RE) and essential oil (Abies alba) containing a-pinene, ?-pinene, camphine, car-3-ene, lemonate bornylacetate, borneol - 15 mg, and excipients: sunflower oil, glycerol, gelatin, caramel (ammonium sulfite) and purified water. In another embodiment, the food supplement comprises other excipients: sorbitol, potassium sorbate, lemon flavour, and purified water.